NON-SMALL CELL LUNG CANCER (NSCLC)
Clinical trials for NON-SMALL CELL LUNG CANCER (NSCLC) explained in plain language.
Never miss a new study
Get alerted when new NON-SMALL CELL LUNG CANCER (NSCLC) trials appear
Sign up with your email to follow new studies for NON-SMALL CELL LUNG CANCER (NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New lung cancer cocktail shows promise in major trial
Disease control CompletedThis study tested a new combination of drugs (tiragolumab plus atezolizumab and chemotherapy) against the current standard treatment (pembrolizumab plus chemotherapy) in 542 people with advanced non-squamous lung cancer who had not been treated before. The goal was to see if the …
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE2, PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 17, 2026 01:41 UTC
-
New hope for lung cancer patients with brain lining spread
Disease control CompletedThis study tested the drug osimertinib in 73 adults with a specific type of lung cancer (EGFR mutation-positive) that had spread to the lining of the brain. The goal was to see if the drug could shrink these tumors and help patients live longer. Participants took one pill daily, …
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New drug combo shows promise in stage 3 lung cancer trial
Disease control CompletedThis study tested whether a combination of two immunotherapy drugs (atezolizumab and tiragolumab) works better than the standard drug durvalumab for people with stage 3 lung cancer that cannot be removed by surgery. Participants had already received chemotherapy and radiation and…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
New combo shrinks lung tumors without chemo in early trial
Disease control CompletedThis study tested a new approach for people with advanced non-small cell lung cancer whose tumors have high levels of a protein called PD-L1. Instead of standard chemotherapy plus radiation, participants received immunotherapy (pembrolizumab) followed by a personalized 4-week cou…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE2 • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
New combo therapy targets advanced lung cancer in early trial
Disease control CompletedThis study tested a new treatment for people with advanced non-small cell lung cancer that had gotten worse after standard treatments. The treatment combined a daily injection of an immune-boosting drug (FLT3 ligand) with targeted radiation to one tumor. The goal was to see if th…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE2 • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jun 11, 2026 12:09 UTC
-
Lung cancer combo before surgery shows promise in Real-World study
Disease control CompletedThis study looked back at medical records of 70 adults in Argentina with a common type of lung cancer (non-small cell lung cancer) that could be removed with surgery. All patients received a combination of the immunotherapy drug nivolumab and chemotherapy before their operation. …
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 09, 2026 12:10 UTC
-
Radiation plus two immunotherapy drugs shows promise in advanced cancers
Disease control CompletedThis early-phase trial tested a new way to treat advanced cancers that have spread. It combined a special type of radiation with two immunotherapy drugs (MEDI4736 and tremelimumab) to see if the combination is safe and tolerable. The study included 53 adults with advanced melanom…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 08, 2026 13:11 UTC
-
Targeted pill shows promise for chinese lung cancer patients with rare gene change
Disease control CompletedThis study tested an oral targeted medicine called capmatinib in 36 Chinese adults with advanced non-small cell lung cancer that has a specific MET gene change (exon 14 skipping). The goal was to see if the drug could shrink or control tumors safely. Participants had not received…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 08, 2026 13:04 UTC
-
Tiny beacons guide lung cancer radiation during breath holds
Knowledge-focused CompletedThis study tested whether small devices called Calypso beacons can help doctors track lung tumors during radiation treatment while patients hold their breath. 48 adults with lung cancer took part. The goal was to see if this tracking method is feasible and accurate, not to cure t…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:05 UTC
-
Sharper scans may help doctors spot lung cancer spread
Knowledge-focused CompletedThis study tested different ways of taking and processing PET/CT images to see if they could more accurately show whether lung cancer has spread to lymph nodes in the chest. Thirty adults with non-small cell lung cancer each had an extra scan session. The goal was to improve stag…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: NA • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jun 10, 2026 13:29 UTC